Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 2/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 4/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR1E | P28566 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2504209 | 0.82 | KDM4E (0.68) | LOXL2KDM4ECYP3A4MAPTNCF1 | |
| SCHEMBL134443 | 0.82 | IDO1 (0.46) | LMNATP53ACACB | |
| SCHEMBL18745617 | 0.81 | NOS1 (0.46) | NOS3NOS1NOS2HTR7HTR1A | |
| SCHEMBL11310162 | 0.79 | ESR1 (0.48) | CYP3A4ALDH1A1LMNATP53ACACB | |
| SCHEMBL8020885 | 0.79 | ESR1 (0.48) | CYP3A4ALDH1A1LMNATP53ACACB | |
| Hydrochloric Acid SCHEMBL30925271 | 0.79 | KDM4E (0.74) | LOXL2KDM4ECYP3A4MAPTNCF1 | |
| SCHEMBL18878186 | 0.79 | HTR7 (0.50) | KDM4ECYP3A4MAPTNOS3NOS1 | |
| SCHEMBL30229907 | 0.77 | LOXL2 (0.47) | LOXL2KDM4ECYP3A4MAPTNCF1 | |
| SCHEMBL14838567 | 0.77 | LOXL2 (0.47) | LOXL2KDM4ECYP3A4MAPTNCF1 | |
| Methyl Alcohol SCHEMBL28236652 | 0.76 | IDO1 (0.42) | ALDH1A1LMNATP53ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964547-A | Urea compound and application thereof as Sigma2 and 5HT2A dual-target inhibitor | 瀚远医药有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230190943-A1 | ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| WO-2021155050-A1 | KINASE MODULATORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021119571-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021051034-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-8741283-B2 | Adenosine deaminase anticancer therapy | SIGMA-TAU RARE DISEASES, S.A. (PT) | 2014-06-03 | — | — | US | disclosed |
| US-8741283-B2 | Adenosine deaminase anticancer therapy | SIGMA-TAU RARE DISEASES, S.A. (PT) | 2014-06-03 | — | — | US | disclosed |
| US-20090047270-A1 | ENZYMATIC ANTICANCER THERAPY | ENZON PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080125363-A1 | Polymer-Linked Pseudomonas Exotoxin Immunotoxin | ENZON PHARMACEUTICALS INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20070166276-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | ENZON PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070166276-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | ENZON PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047270-A1 | ENZYMATIC ANTICANCER THERAPY | RNASE1, ADA, DCTD | LOXL2 1138/4885KDM4E 2410/4885CYP3A4 1061/4885 |
| US-20070166276-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | CD44, PAICS, ALG1 | LOXL2 967/4885KDM4E 3300/4885CYP3A4 2002/4885 |
| US-20230190943-A1 | ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND | ALG1, ALG8, ALG3 | LOXL2 171/4885KDM4E 3790/4885CYP3A4 4663/4885 |
| US-20080125363-A1 | Polymer-Linked Pseudomonas Exotoxin Immunotoxin | CD47, SPG11, ALG1 | LOXL2 3601/4885KDM4E 3924/4885CYP3A4 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.